CN1441677A - 抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用 - Google Patents

抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用 Download PDF

Info

Publication number
CN1441677A
CN1441677A CN01808874A CN01808874A CN1441677A CN 1441677 A CN1441677 A CN 1441677A CN 01808874 A CN01808874 A CN 01808874A CN 01808874 A CN01808874 A CN 01808874A CN 1441677 A CN1441677 A CN 1441677A
Authority
CN
China
Prior art keywords
antibodies
antibody
cytokine
cell
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN01808874A
Other languages
English (en)
Chinese (zh)
Inventor
N·翰纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idec Pharmaceuticals Corp
Original Assignee
Idec Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idec Pharmaceuticals Corp filed Critical Idec Pharmaceuticals Corp
Publication of CN1441677A publication Critical patent/CN1441677A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN01808874A 2000-03-31 2001-04-02 抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用 Pending CN1441677A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19346700P 2000-03-31 2000-03-31
US60/193,467 2000-03-31

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2006101439863A Division CN1981868A (zh) 2000-03-31 2001-04-02 抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用

Publications (1)

Publication Number Publication Date
CN1441677A true CN1441677A (zh) 2003-09-10

Family

ID=22713760

Family Applications (2)

Application Number Title Priority Date Filing Date
CN01808874A Pending CN1441677A (zh) 2000-03-31 2001-04-02 抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用
CNA2006101439863A Pending CN1981868A (zh) 2000-03-31 2001-04-02 抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2006101439863A Pending CN1981868A (zh) 2000-03-31 2001-04-02 抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用

Country Status (12)

Country Link
US (2) US6896885B2 (enExample)
EP (1) EP1283722A1 (enExample)
JP (1) JP2004500412A (enExample)
KR (1) KR20020091170A (enExample)
CN (2) CN1441677A (enExample)
AU (2) AU2001287291B2 (enExample)
BR (1) BR0109705A (enExample)
CA (1) CA2404365A1 (enExample)
MX (1) MXPA02009626A (enExample)
NO (1) NO20024682L (enExample)
WO (1) WO2001074388A1 (enExample)
ZA (1) ZA200207847B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107001472A (zh) * 2014-11-10 2017-08-01 免疫医疗有限公司 对cd73具有特异性的结合分子及其用途

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030180290A1 (en) * 1995-06-07 2003-09-25 Idec Pharmaceuticals Corporation Anti-CD80 antibody having ADCC activity for ADCC mediated killing of B cell lymphoma cells alone or in combination with other therapies
US7696325B2 (en) 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis
KR20020027311A (ko) * 1999-05-07 2002-04-13 제넨테크, 인크. Ｂ 세포 표면 마커에 결합하는 길항물질을 이용한자가면역 질환의 치료
HK1047702A1 (zh) * 1999-07-12 2003-03-07 Genentech Inc. 用与cd20结合的拮抗剂阻断对外来抗原的免疫应答
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
PT1255558E (pt) * 2000-02-16 2006-11-30 Genentech Inc Anticorpos anti-april e células hibridoma
EP1283722A1 (en) 2000-03-31 2003-02-19 Idec Pharmaceuticals Corporation Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
CN1592645A (zh) * 2000-09-18 2005-03-09 拜奥根Idec公司 使用b细胞耗尽/免疫调节抗体组合治疗自身免疫病的联合疗法
ATE391174T1 (de) 2000-10-20 2008-04-15 Chugai Pharmaceutical Co Ltd Modifizierter tpo-agonisten antikörper
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20020159996A1 (en) * 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
JP4463475B2 (ja) * 2001-01-31 2010-05-19 バイオジェン アイデック インコーポレイテッド 腫瘍疾患の治療における免疫調節性抗体の使用
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
US6916814B2 (en) * 2001-07-11 2005-07-12 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating cytokine mediated diseases
KR20040019105A (ko) * 2001-08-03 2004-03-04 제넨테크, 인크. ＴＡＣＩｓ 및 ＢＲ3 폴리펩티드 및 이의 용도
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
WO2003039486A2 (en) * 2001-11-09 2003-05-15 Idec Pharmaceuticals Corporation Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
TW200303759A (en) * 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
US8287864B2 (en) * 2002-02-14 2012-10-16 Immunomedics, Inc. Structural variants of antibodies for improved therapeutic characteristics
WO2003074567A2 (en) * 2002-03-01 2003-09-12 Immunomedics, Inc. Internalizing anti-cd74 antibodies and methods of use
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US20070207142A1 (en) * 2002-05-08 2007-09-06 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US20030219818A1 (en) * 2002-05-10 2003-11-27 Bohen Sean P. Methods and compositions for determining neoplastic disease responsiveness to antibody therapy
AU2003256836A1 (en) * 2002-07-25 2004-02-16 Genentech, Inc. Taci antibodies and uses thereof
WO2004035607A2 (en) * 2002-10-17 2004-04-29 Genmab A/S Human monoclonal antibodies against cd20
WO2004045526A2 (en) * 2002-11-15 2004-06-03 Morehouse School Of Medicine Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
PT1572744E (pt) * 2002-12-16 2010-09-07 Genentech Inc Variantes de imunoglobulina e utilizações destas
EP1444989A1 (en) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
JP2004279086A (ja) 2003-03-13 2004-10-07 Konica Minolta Holdings Inc 放射線画像変換パネル及び放射線画像変換パネルの製造方法
JPWO2004087763A1 (ja) * 2003-03-31 2006-07-27 中外製薬株式会社 Ｃｄ２２に対する改変抗体およびその利用
HRP20090325T1 (en) * 2003-04-09 2009-07-31 Genentech Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
US20110042260A1 (en) * 2003-04-10 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
NZ543960A (en) 2003-05-09 2008-11-28 Univ Duke CD20-specific antibodies and methods of employing same
EP2272868B1 (en) 2003-06-05 2015-03-04 Genentech, Inc. Combination therapy for B cell disorders
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
CN1860367B (zh) * 2003-07-29 2010-05-26 健泰科生物技术公司 人抗cd20抗体的测定法及其用途
ZA200601218B (en) * 2003-08-29 2007-05-30 Genentech Inc Anti-CD20 therapy of ocular disorders
WO2005042019A1 (en) * 2003-10-22 2005-05-12 University Of Rochester Anti-thymocyte antiserum and use thereof to trigger b cell apoptosis
ME01775B (me) * 2003-11-05 2011-02-28 Glycart Biotechnology Ag Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
EP1682179A4 (en) * 2003-11-05 2008-09-03 Palingen Inc IMPROVED B-CELL CYTOTOXICITY OF CDIM BINDING ANTIBODY
NZ596984A (en) * 2003-11-17 2013-10-25 Genentech Inc Compositions and methods for the treatment of tumor of hematopoietic origin
CA2549122A1 (en) * 2003-12-19 2005-07-07 Genentech, Inc. Detection of cd20 in therapy of autoimmune diseases
CN1918181A (zh) * 2003-12-19 2007-02-21 健泰科生物技术公司 移植排斥中cd20的检测
US20050136055A1 (en) * 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
AU2012200431B2 (en) * 2004-04-09 2013-06-27 Fondazione Irccs Istituto Nazionale Dei Tumori Gene expression markers for predicting response to chemotherapy
JP2007532681A (ja) * 2004-04-16 2007-11-15 ジェネンテック・インコーポレーテッド Ｂ細胞の枯渇を増大させる方法
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
BRPI0510224A (pt) * 2004-05-05 2007-10-23 Genentech Inc métodos de prevenção de doença autoimunológica e artigo industrializado
EP1753455A2 (en) 2004-06-04 2007-02-21 Genentech, Inc. Method for treating multiple sclerosis
AU2005251764A1 (en) * 2004-06-04 2005-12-22 Genentech, Inc. Method for treating lupus
MX2007000327A (es) * 2004-07-09 2007-03-12 Schering Ag Tratamiento del linfoma de celulas b.
US20060062787A1 (en) * 2004-07-22 2006-03-23 Genentech, Inc. Method for treating Sjogren's syndrome
AU2005269820B2 (en) * 2004-07-22 2009-03-26 Early Detection Llc Methods for diagnosis using anti-cytokine receptor antibodies
BRPI0514068B8 (pt) 2004-08-04 2021-05-25 Applied Molecular Evolution Inc anticorpo anti-cd20, e, composição farmacêutica
SG165344A1 (en) * 2004-10-05 2010-10-28 Genentech Inc Method for treating vasculitis
AU2005335217A1 (en) * 2004-10-05 2007-02-15 Ochsner Clinic Foundation Enhancement of B cell proliferation by IL-15
WO2006076651A2 (en) * 2005-01-13 2006-07-20 Genentech, Inc. Treatment method
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US9493569B2 (en) 2005-03-31 2016-11-15 Chugai Seiyaku Kabushiki Kaisha Structural isomers of sc(Fv)2
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
AR053579A1 (es) * 2005-04-15 2007-05-09 Genentech Inc Tratamiento de la enfermedad inflamatoria intestinal (eii)
PL1874821T3 (pl) * 2005-04-26 2013-09-30 Trion Pharma Gmbh Kombinacja przeciwciał i glikokortykoidów do leczenia raka
CN1865275B (zh) 2005-05-17 2011-06-15 长春华普生物技术有限公司 对人b细胞肿瘤有治疗作用的人工合成的单链脱氧核苷酸
CN101223448B (zh) * 2005-05-20 2012-01-18 健泰科生物技术公司 来自自身免疫病受试者的生物学样品的预处理
FR2886298A1 (fr) * 2005-05-24 2006-12-01 Ifremer Anticorps ou fragment d'anticorps couple a un agent immunogene
EP1908482B1 (en) 2005-06-10 2017-09-06 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
KR101360671B1 (ko) 2005-06-10 2014-02-07 추가이 세이야쿠 가부시키가이샤 ｓｃ（Ｆｖ）２를 함유하는 의약조성물
HUE026303T2 (hu) 2005-07-25 2016-06-28 Emergent Product Dev Seattle B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
BRPI0614183A2 (pt) 2005-07-25 2011-03-15 Trubion Pharmaceuticals Inc uso de dose única de moléculas de ligação especìficas para cd20
EP1916997B1 (en) 2005-08-05 2018-04-18 Amgen Inc. Stable aqueous protein pharmaceutical formulations and their preparation
US20070172847A1 (en) * 2005-11-15 2007-07-26 The Regents Of The University Of California Molecular signaling pathways triggered by rituximab: prognostic, diagnostic, and therapeutic uses
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
CA2629306A1 (en) * 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
US20070136826A1 (en) * 2005-12-02 2007-06-14 Biogen Idec Inc. Anti-mouse CD20 antibodies and uses thereof
EP2009101B1 (en) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
HRP20140172T1 (hr) 2006-05-30 2014-03-28 Genentech, Inc. Protutijela i imunokonjugati kao i njihove uporabe
CN105837690A (zh) * 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
AU2007263265A1 (en) * 2006-06-21 2007-12-27 Apogenix Gmbh Differential IL-4 and/or IL-10 cytokine expression in human cancer
US20100086515A1 (en) * 2006-07-06 2010-04-08 Apogenix Gmbh Human il-4 muteins in cancer therapy
EP2975057A1 (en) * 2006-07-10 2016-01-20 Fujita Health University Novel anti-cd73 antibody
CN103694349A (zh) * 2006-09-08 2014-04-02 米迪缪尼有限公司 人源化抗cd19抗体及其在治疗癌症、移植病和自身免疫病中的应用
NO346530B1 (no) 2006-09-28 2022-09-26 Merck Sharp & Dohme Anvendelser av pegylert interleukin-10 (PEG-IL-10) for å forebygge metastaser av kreft eller tumor i lungene.
WO2008043072A2 (en) * 2006-10-05 2008-04-10 Biogen Idec Inc. Cd80 antagonists for treating neoplastic disorders
CA2690898A1 (en) 2007-06-08 2008-12-18 Biogen Idec Ma Inc. Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
WO2009009523A2 (en) 2007-07-09 2009-01-15 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
MY150531A (en) 2007-07-16 2014-01-30 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
RU2557319C2 (ru) 2007-07-16 2015-07-20 Дженентек, Инк. ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ CD79b И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ПРИМЕНЕНИЯ
WO2009052293A1 (en) 2007-10-16 2009-04-23 Zymogenetics, Inc. Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
US7902147B2 (en) * 2007-11-05 2011-03-08 Duke University Chronic lymphocytic leukemia prognosis and treatment
EP2077281A1 (en) * 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
DK2657253T3 (en) 2008-01-31 2017-10-09 Genentech Inc Anti-CD79b antibodies and immune conjugates and methods of use
AU2009234277B2 (en) 2008-04-11 2014-12-04 Aptevo Research And Development Llc CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
TW201438738A (zh) 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
KR20110083730A (ko) * 2008-11-13 2011-07-20 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 Ｃｄ37 면역치료제 병용 요법 및 이의 용도
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
US20110142836A1 (en) * 2009-01-02 2011-06-16 Olav Mella B-cell depleting agents for the treatment of chronic fatigue syndrome
SI2464725T2 (sl) 2009-08-11 2025-06-30 F. Hoffmann-La Roche Ag Proizvodnja beljakovin v medijih za celične kulture brez glutamina
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
US9173961B2 (en) 2010-02-10 2015-11-03 Immunogen, Inc. CD20 antibodies and uses thereof
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3431485B2 (en) 2010-10-01 2024-09-04 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
WO2013096346A1 (en) * 2011-12-22 2013-06-27 Development Center For Biotechnology Bispecific t-cell activator antibody
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
CA2892529C (en) 2012-11-26 2023-04-25 Moderna Therapeutics, Inc. Terminally modified rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
ES2881306T3 (es) 2013-09-27 2021-11-29 Chugai Pharmaceutical Co Ltd Método para la producción de heteromultímeros de polipéptidos
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
KR101723786B1 (ko) 2014-03-28 2017-04-06 가톨릭대학교 산학협력단 Ｉｌ―２１을 발현하는 중간엽 줄기세포를 포함하는 ｂ 세포 림프종 예방 또는 치료용 조성물
DK3262071T3 (da) 2014-09-23 2020-06-15 Hoffmann La Roche Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
HRP20201756T8 (hr) 2014-11-21 2021-08-20 Bristol-Myers Squibb Company Antitijela koja sadrže modificirane regije teškog lanca
DK3221363T3 (da) 2014-11-21 2020-08-10 Bristol Myers Squibb Co Antistoffer mod cd73 og anvendelser deraf
IL302486A (en) 2015-06-24 2023-06-01 Hoffmann La Roche Antibodies against the transnephrine receptor with adapted affinity
EP3341012B1 (en) 2015-08-25 2025-07-30 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
JP6657392B2 (ja) 2015-10-02 2020-03-04 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗ヒトｃｄ２０／ヒトトランスフェリン受容体抗体及び使用方法
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
JP7219005B2 (ja) 2015-12-28 2023-02-07 中外製薬株式会社 Ｆｃ領域含有ポリペプチドの精製を効率化するための方法
EP3551047A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
AU2018222735B2 (en) 2017-02-17 2023-04-27 George Todaro Use of TGF alpha for the treatment of diseases and disorders
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2018187074A1 (en) 2017-04-03 2018-10-11 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
CN116726362A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US6217857B1 (en) 1989-06-28 2001-04-17 Schering Corporation Cytokine synthesis inhibitory factor (IL-10) and pharmaceutical compositions thereof
US5231012A (en) 1989-06-28 1993-07-27 Schering Corporation Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10)
IL94878A (en) 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same
US5124471A (en) 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
US6018036A (en) 1990-06-29 2000-01-25 Schering Corporation Nucleic acids encoding cytokine synthesis inhibitory factor (Interleukin-10)
US6106823A (en) 1991-01-16 2000-08-22 Schering Corporation Treatment of neoplastic disease with interleukin-10
US5833976A (en) 1991-08-06 1998-11-10 Schering Corporation Use of interleukin-10 (IL-10) to treat endotoxin- or superantigen-induced toxicity
KR0170037B1 (ko) 1992-08-20 1999-02-01 에릭 에스. 딕커 인터루킨-4 및/또는 인터루킨-10을 함유하는 약제학적 조성물
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5789192A (en) 1992-12-10 1998-08-04 Schering Corporation Mammalian receptors for interleukin-10 (IL-10)
TW381026B (en) * 1993-01-13 2000-02-01 Schering Corp Method of extracorporally activating cytolytic activity of peripheral blood mononuclear cells and pharmaceutical composition comprising the activated peripheral blood mononuclear cells
WO1994016727A1 (en) * 1993-01-29 1994-08-04 Vetrepharm, Inc. Immunotherapeutic composition
NZ269663A (en) 1993-07-26 1997-09-22 Schering Corp Agonists and antagonists of il-10
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5698443A (en) * 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
US5639600A (en) * 1994-08-05 1997-06-17 The Regents Of The University Of California Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement
ATE306930T1 (de) 1994-08-12 2005-11-15 Immunomedics Inc Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
US5716612A (en) * 1994-09-07 1998-02-10 Schering Corporation Use of IL-4 for potentiation of chemotherapeutic agents
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US5770190A (en) * 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10
DE29512719U1 (de) 1995-07-28 1996-08-29 Glaser, Ralf, Dr.rer.nat., 10178 Berlin Monoklonale Antikörper gegen humanes Interleukin-10
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6183744B1 (en) * 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US5863790A (en) * 1997-05-14 1999-01-26 Minnesota Mining And Manfacturing Company Biological sterility indicator
DK0999853T3 (da) 1997-06-13 2003-04-22 Genentech Inc Stabiliseret antostofformulering
JP2002522511A (ja) * 1998-08-11 2002-07-23 アイデック ファーマスーティカルズ コーポレイション 抗ｃｄ２０抗体の投与を含むｂ細胞リンパ腫の併用療法
US6224866B1 (en) 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
EP1283722A1 (en) 2000-03-31 2003-02-19 Idec Pharmaceuticals Corporation Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
US6877180B2 (en) * 2002-09-06 2005-04-12 Tennant Street sweeper main broom cutoff flap

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107001472A (zh) * 2014-11-10 2017-08-01 免疫医疗有限公司 对cd73具有特异性的结合分子及其用途

Also Published As

Publication number Publication date
US20020012665A1 (en) 2002-01-31
AU8729101A (en) 2001-10-15
MXPA02009626A (es) 2003-05-14
NO20024682L (no) 2002-12-02
US20050180975A1 (en) 2005-08-18
JP2004500412A (ja) 2004-01-08
NO20024682D0 (no) 2002-09-30
CA2404365A1 (en) 2001-10-11
ZA200207847B (en) 2005-04-07
AU2001287291B2 (en) 2006-08-10
KR20020091170A (ko) 2002-12-05
WO2001074388A1 (en) 2001-10-11
BR0109705A (pt) 2005-01-11
CN1981868A (zh) 2007-06-20
US6896885B2 (en) 2005-05-24
EP1283722A1 (en) 2003-02-19

Similar Documents

Publication Publication Date Title
CN1441677A (zh) 抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用
JP6143664B2 (ja) Ｂ細胞表面マーカーに結合するアンタゴニストを用いた自己免疫疾患の治療
JP5746243B2 (ja) ＴＮＦαインヒビターに対して不十分な反応を示す患者の自己免疫疾患治療法
CN1437478A (zh) 瑞图希单抗的鞘内施用,用于中枢神经系统淋巴瘤的治疗
CN1592645A (zh) 使用b细胞耗尽/免疫调节抗体组合治疗自身免疫病的联合疗法
AU2001287291A1 (en) Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for the treatment of B cell lymphoma
JP2004512262A (ja) 非放射性抗ｃｄ２０抗体／放射標識抗ｃｄ２２抗体の組合せ
JP2007504138A (ja) 眼疾患の治療法
JP2008507473A (ja) 移植片拒絶におけるｃｄ２０の検出
CN1917901A (zh) 自身免疫病疗法中cd20的检测
EP1649870A2 (en) Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
HK1057867A (en) Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
HK1058315A (en) Intrathecal administration of rituximab for treatment of central nervous system lymphomas
HK1087639A (en) Intrathecal administration of rituximab for treatment of central nervous system lymphomas
HK1086506A (en) Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
HK1086504A (en) Treatment of autoimmune diseases with antagonists which bind to b cell surface markers

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1057867

Country of ref document: HK